Company Overview
Company Type: Public Company
Website: www.ondinebio.com
Number of Employees: 18
Ticker: OBI (AIM)
Year Founded: 1996


Business Description
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The companyâ€™s lead product is Steriwave, a photodisinfection-based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces viral titres and transmission of respiratory viruses, such as SARS-CoV-2, influenza, RSV, etc.; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.8
Market Capitalization
27.7
TEV/Total Revenue
30.2x
EBITDA
(18.2)
Total Enterprise Value
24.3
TEV/EBITDA
NM
EBIT
(18.4)
Cash & ST Invst.
4.4
P/Diluted EPS Before Extra
NM
Net Income
(18.7)
Total Debt
1.0
Price/Tang BV
6.7x
Capital Expenditure
(0.2)
Total Assets
7.4
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
-
-
(0.07)
(0.06)
(0.07)
Revenue (mm)
-
-
1.30
2.28
1.30
EBITDA (mm)
-
-
(16.39)
(17.36)
(16.39)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
18.06x
TEV/EBITDA
NM
P/BV
2.69x

Non-Periodic Estimates

Recommendation
Buy (1.50)
Target Price
0.96
Potential Upside
596.97%


Key Professionals
Name
Title
Cross, Carolyn M.
Founder, CEO & Executive Director
Loebel, Nicolas G.
President, CTO & Executive Director
Shah, Vipul 
VP & CFO
Vance, Angelika 
Vice President of Corporate Communications
Sinclair, Simon 
Chief Medical Officer & Director
Parkhaev, Nikita 
Company Secretary

Key Board Members
Name
Title
Charest, Jean 
Independent Chairman of the Board
Cross, Carolyn M.
Founder, CEO & Executive Director
Loebel, Nicolas G.
President, CTO & Executive Director
Sinclair, Simon 
Chief Medical Officer & Director
Duvall, Jean Marie
Senior Independent Non-Executive Director
Garthwaite, Thomas L.
Chairman of Medical Advisory Board
Rose, Timothy
Chairman of Clinical Advisory Board
Tooman, Craig A.
Independent Non-Executive Director
Bajwa, Junaid Sam
Independent Non-Executive Director
Biel, Merrill Abraham
Member of Clinical Advisory Board
Bruce, Steve
Member of Clinical Advisory Board
Chadwick, Greg
Member of Clinical Advisory Board


Primary Industry Classification
Health Care Equipment


Primary Office Location
1100 Melville Street Suite 888 | Vancouver, BC | V6E 4A6 | Canada
Phone: 604-669-0555   Fax: 604-669-0533

Current and Pending Investors
Bipper Trading Inc., Courthill Foundation, Endowment Arm

Prior Investors
Advanced Photodynamic Technologies, Inc., Cross Family Trust, The Windham Foundation, Inc., UCL Business Ltd

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.14
Market Cap (mm)
26.9
Open
 0.14
Shares Out. (mm)
195.1
Previous Close
 0.14
Float %
42.7%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
(2.9)%
Dividend Yield %
-
Day High/Low
 0.13/ 0.13
Diluted EPS Excl. Extra Items
(0.10)
52 wk High/Low
 0.49/ 0.13
P/Diluted EPS Before Extra
NM
Volume (mm)
0.09
Avg 3M Dly Vlm (mm)
0.09
Beta 5Y
-


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
AIM:OBI - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Advanced Photodynamic Technologies, Inc.
Advanced Photodynamic Technologies, Inc. engages in research and development of photodynamic drugs and devices for antimicrobial and oncotherapeutic applications. The company has developed devices used for reduction of ventilator-associated pneumonia. Advanced Photodynamic Technologies, Inc. was founded in 1996 and is based in Minneapolis, Minnesota  As of December 7, 2009, Advanced Photodynamic Technologies, Inc. operates as a subsidiary of Ondine Biopharma Corp.

United States and Canada
Biotechnology
-
-
-
Springbank Ventures Inc.
Springbank Ventures, Inc. acquired Ondine Biopharma, Inc. in March 2004 in a transaction that was accounted for as the recapitalization of Ondine Biopharma. Previously, Springbank Ventures was engaged in the acquisition and exploration of mineral properties in Canada. The company was formerly known as formerly Mutapa Copper and Cobalt, Inc.

United States and Canada
Diversified Metals and Mining
-
2.00
0.00
Ondine Biopharma (U.S.A.), Inc.
Ondine Biopharma (U.S.A.), Inc.,  develops novel, photocidal therapies for the treatment of microbial infections of the oral cavity. The company is based in Cincinnati, Ohio. It operates as a subsidiary of Ondine Biopharma Corp.

United States and Canada
Biotechnology
-
-
-
Ondine Research Laboratories Inc.
Ondine Research Laboratories Inc. conducts research for the development of laser-activated anti-microbial technology. The company is based in Canada. Ondine Research Laboratories Inc. is based in Ondine Biopharma Corp.

United States and Canada
Research and Consulting Services
-
-
-
Sinuwave Technologies Corporation
Sinuwave Technologies Corporation intends to develop and commercialize photo disinfection technology for the treatment of Chronic Sinusitis. The company was founded in 2010 and is based in Vancouver, Canada.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-1-2021
Dec-6-2021
Public Offering
Target
Ondine Biomedical Inc. (AIM:OBI)


137.71
Jun-28-2011
Sep-6-2011
Merger/Acquisition
Target
Ondine Biomedical Inc. (AIM:OBI)
Bipper Trading Inc.,Courthill Foundation, Endowment Arm
Cross Family Trust,Advanced Photodynamic Technologies, Inc.,The Windham Foundation, Inc.
3.73
Dec-24-2010
Dec-24-2010
Private Placement
Target
Ondine Biomedical Inc. (AIM:OBI)


0.67
Jul-7-2010
Sep-13-2010
Merger/Acquisition
Seller
Sinuwave Technologies Corporation
B&W Partners AG,Tonga Finance and Trading AG
Ondine Biopharma Corp. (nka:Ondine Biomedical Inc. (AIM:OBI)),Advanced Photodynamic Technologies, Inc.
0.91
Apr-6-2010
Apr-26-2010
Public Offering
Target
Ondine Biopharma Corp. (nka:Ondine Biomedical Inc. (AIM:OBI))


0.83
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-29-2023
Client Announcements
Burnaby Hospital Deploys Steriwave Burnaby Hospital to Help Prevent Surgical Site Infections and Optimize Patient Outcomes
Sep-25-2023
Earnings Calls
Ondine Biomedical Inc., H1 2023 Earnings Call, Sep 25, 2023
Sep-12-2023
Company Conference Presentations
Ondine Biomedical Inc. Presents at 7th International Consortium on Prevention & nfection Control, Sep-12-2023
Jul-07-2023
Product-Related Announcements
Ondine Biomedical Inc. Announces Updated Phase 3 Clinical Trial
Jun-01-2023
Executive/Board Changes - Other
Ondine Biomedical Appoints Dr. Simon Sinclair as Chief Medical Officer

M&A Advisors
Canaccord Genuity Limited, Canaccord Genuity LLC, Dentons Canada LLP, Evans & Evans, Inc.


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Canaccord Genuity Limited, Canaccord Genuity LLC, Dentons Canada LLP, Evans & Evans, Inc.
Private Placement Advisors
Canaccord Genuity Corp., Canaccord Genuity Limited, Haywood Securities Inc., MGI Securities Inc.
Public Offering Advisors
Arden Partners plc, DuMoulin Black LLP, Ernst & Young LLP (Canada), Lang Michener LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
CFRA Equity Research

Oct 01, 2023 09:13 PM
OBI
Ondine Biomedical Inc.
Reports
9
RBC Capital Markets
Reynolds-Clark, Jack
Sep 25, 2023 03:18 AM
OBI
OBI: H1 results: progress towards Phase 3 trial
Reports
6
GlobalData

Sep 15, 2023 07:50 AM
OBI
Ondine Biomedical Inc (OBI.LON) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
28
GlobalData

Sep 15, 2023 04:41 AM
OBI
Ondine Biomedical Inc (OBI.LON) - Medical Devices Product Pipeline Summary
Reports
55
GlobalData

Sep 11, 2023 01:23 AM
OBI
Ondine Biomedical Inc (OBI.LON) - Financial Analysis Review
Reports
131
Edison Investment Research
Romanoff, Soo
Aug 11, 2023 02:58 AM
OBI
Ondine Biomedical - Steriwave initiates UK pilot study with NHS
Reporting Results*
2
Auerbach Grayson

Aug 07, 2023 08:08 AM
OBI
AUERBACH GRAYSON: Ondine Biomedical - Pilot study roll out continues (United Kingdom)
Reports
6
Auerbach Grayson

Aug 01, 2023 07:11 AM
OBI
AUERBACH GRAYSON: Ondine Biomedical - First NHS pilot study initiated (United Kingdom)
Initiation of Coverage*
6
GlobalData

Jun 09, 2023 10:33 AM
OBI
Ondine Biomedical Inc (OBI.LON) - Medical Devices Product Pipeline Summary
Reports
52
GlobalData

Jun 09, 2023 04:45 AM
OBI
Ondine Biomedical Inc (OBI.LON) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
28


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Cross C.F.A., CFA, M.B.A., MBA, Carolyn M.

108,376,109

55.56

16.6

Dec-31-2022


Lansdowne Partners Limited

9,298,090

4.77

1.4

Jan-12-2023


Chelverton Asset Management Limited

7,957,311

4.08

1.2

Dec-31-2022


Janus Henderson Group plc

3,999,979

2.05

0.6

Jun-30-2023


Loebel Ph.D., Nicolas G.

2,633,334

1.35

0.4

Dec-31-2022


Aegon Asset Management UK Plc

1,129,231

0.58

0.2

Jan-31-2023


Premier Fund Managers Ltd.

1,035,284

0.53

0.2

May-31-2023


Charest, Jean 

353,356

0.18

0.1

Dec-31-2022


Sinclair Ph.D., Simon 

256,327

0.13

0.0

Dec-31-2022


Bajwa, Junaid Sam

127,125

0.07

0.0

Dec-31-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Lansdowne Partners Limited
9,298,090
9,298,090

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Janus Henderson Group plc
3,999,979
(63,482)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-13
Ondine to present new AMR research at ICPIC, Geneva
India Pharma News


Company Coverage
This company is not on any Coverage List.

Products
Anti-MRSA Photodisinfection Agents, MRSAid Photodisinfection System (Future), Multi-Purpose Photodisinfection Laser, OND1002 (Future), OND1003 (Future), OND1004 (Future), OND1005 (Future), Periowave, Sinuwave (Future), Steriwave, Uriwave (Future)


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-29-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Non Regulatory Announcement
19 KB
Sep-25-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Interim Results
312 KB
Sep-21-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Non Regulatory Announcement
26 KB
Sep-14-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Non Regulatory Announcement
16 KB
Sep-12-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Non Regulatory Announcement
15 KB
Aug-30-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Notice of Results
12 KB
Aug-29-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Non Regulatory Announcement
16 KB
Aug-07-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Non Regulatory Announcement
22 KB
Jul-17-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Non Regulatory Announcement
13 KB
Jun-22-2023
Ondine Biomedical Inc. (AIM:OBI)
RNS
Non Regulatory Announcement
18 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Shah, Vipul  (VP & CFO)
Nov-02-2022
New Common Shares
15,000
5,784
Open Market Acquisition
30.00
Exchange Announcement
Shah, Vipul  (VP & CFO)
Oct-24-2022 - Oct-25-2022
New Common Shares
50,000
19,603
Open Market Acquisition
New
Exchange Announcement
-
Oct-24-2022
New Common Shares
15,000
5,819
Open Market Acquisition
-
Exchange Announcement
-
Oct-24-2022
New Common Shares
10,000
3,918
Open Market Acquisition
-
Exchange Announcement
-
Oct-25-2022
New Common Shares
25,000
9,866
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Charest, Jean 
Independent Chairman of the Board
604-669-0555
604-669-0533

Cross, Carolyn M.
Founder, CEO & Executive Director
+1 604 669 0555
604-669-0533
ccross@ondinebiopharma.com
Loebel, Nicolas G.
President, CTO & Executive Director
604-669-0555
604-669-0533

Sinclair, Simon 
Chief Medical Officer & Director
604-669-0555
604-669-0533

Duvall, Jean Marie
Senior Independent Non-Executive Director
604-669-0555
604-669-0533

Garthwaite, Thomas L.
Chairman of Medical Advisory Board
604-669-0555
604-669-0533
-
Rose, Timothy
Chairman of Clinical Advisory Board
604-669-0555
604-669-0533
-
Tooman, Craig A.
Independent Non-Executive Director
(913) 353-1026
604-669-0533

Bajwa, Junaid Sam
Independent Non-Executive Director
604-669-0555
604-669-0533

Biel, Merrill Abraham
Member of Clinical Advisory Board
604-669-0555
604-669-0533
Bielx001@umn.edu
Bruce, Steve
Member of Clinical Advisory Board
604-669-0555
604-669-0533
-
Chadwick, Greg
Member of Clinical Advisory Board
604-669-0555
604-669-0533
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Cross, Carolyn M.
Founder, CEO & Executive Director
+1 604 669 0555
604-669-0533
ccross@ondinebiopharma.com
Loebel, Nicolas G.
President, CTO & Executive Director
604-669-0555
604-669-0533

Shah, Vipul 
VP & CFO
604-669-0555
604-669-0533

Vance, Angelika 
Vice President of Corporate Communications
604-669-0555
604-669-0533

Sinclair, Simon 
Chief Medical Officer & Director
604-669-0555
604-669-0533

Parkhaev, Nikita 
Company Secretary
604-669-0555
604-669-0533

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâ€™S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâ€™s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
